1. Pink Sheet
  2. >>Geography

EU Proposal Seeks To Address Borderline Product Classification ‘As Early As Possible’

 
• By Neena Brizmohun

The European Commission’s draft regulation for reforming the EU medicines legislation has proposed a new product classification mechanism for borderline cases where it is not clear if a product is a medicine or falls under another area such as medical devices.

Pills or capsules as a question mark and white plastic bottle.
For borderline cases it can be unclear if a product is a medicine • Source: Shutterstock

The European Commission has proposed introducing a new mechanism for classifying whether a product under development is a medicine in situations where there are borderline issues and it is unclear whether the product is, for example, a drug, a medical device or a cosmetic.

Under the proposal, the European Medicines Agency would be empowered to give scientific recommendations on whether a product that could...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

US FDA Will Not Pull Teva And MSN Hetlioz ANDAs, Rejects Vanda Citizen Petitions

 
• By Dean Rudge

The FDA concluded that generic tasimelteon products held by Teva and MSN Labs meet all statutory bioequivalence requirements and there was no “mistake” or untrue statement in the original ANDA approvals.

AI And Inertia: The Disruptors Keeping EU Regulators Awake At Night

 
• By Francesca Bruce

Data is “the new oil,” but its use will challenge regulators, while inertia is the biggest disrupter of all for European regulators, according to European Medicines Agency chiefs past and present.

AI In Manufacturing: EU To Revamp GMP Guidance In Light Of Digital Advancements

 
• By Eliza Slawther

Pharma firms are being encouraged to respond to a European Commission consultation on planned updates to its good manufacturing practice standards which reflect the “rapid advancement” of modern technologies, like AI and digital systems, in drug manufacturing.